Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience

Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience

<b>Background:</b> Immune checkpoint inhibitors (ICIs) have widened the therapeutic scenario of different solid tumors over the last ten years. Gastrointestinal (GI) adverse events (AEs), such as diarrhea and colitis, occur in up to 50% of patients treated with ICIs. <b>Materials a...

Full description

Bibliographic Details
Main Authors: Paola Parente, Brigida Anna Maiorano, Davide Ciardiello, Francesco Cocomazzi, Sonia Carparelli, Maria Guerra, Giuseppe Ingravallo, Gerardo Cazzato, Illuminato Carosi, Evaristo Maiello, Fabrizio Bossa
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Diagnostics
Subjects:
immune checkpoint inhibitor
ICI
diarrhea
colitis
PD1
PD-L1
Online Access:https://www.mdpi.com/2075-4418/12/3/685

Similar Items

Similar Items